Definitive Healthcare Corp. (NASDAQ:DH) Short Interest Down 23.2% in December

Definitive Healthcare Corp. (NASDAQ:DH) was the target of a significant decline in short interest during the month of December. As of December 31st, there was short interest totaling 2,248,253 shares, a decline of 23.2% from the December 15th total of 2,928,539 shares. Approximately 1.9% of the company’s stock are short sold. Based on an average daily trading volume, of 774,861 shares, the short-interest ratio is presently 2.9 days. Based on an average daily trading volume, of 774,861 shares, the short-interest ratio is presently 2.9 days. Approximately 1.9% of the company’s stock are short sold.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the stock. Barclays decreased their price objective on shares of Definitive Healthcare from $3.00 to $2.75 and set an “underweight” rating for the company in a report on Monday, December 8th. William Blair upgraded Definitive Healthcare to a “strong-buy” rating in a research note on Thursday, November 6th. Wall Street Zen lowered Definitive Healthcare from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 28th. Canaccord Genuity Group reduced their target price on Definitive Healthcare from $5.00 to $4.00 and set a “hold” rating on the stock in a report on Monday, November 10th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Definitive Healthcare in a report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, three have issued a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat.com, Definitive Healthcare currently has an average rating of “Hold” and a consensus target price of $3.94.

Definitive Healthcare Stock Performance

DH stock traded down $0.04 during midday trading on Friday, reaching $2.39. The company had a trading volume of 245,366 shares, compared to its average volume of 496,620. The firm has a market capitalization of $337.85 million, a PE ratio of -1.43 and a beta of 1.60. The stock has a 50 day moving average price of $2.59 and a 200 day moving average price of $3.31. Definitive Healthcare has a fifty-two week low of $2.15 and a fifty-two week high of $5.68. The company has a quick ratio of 1.60, a current ratio of 1.60 and a debt-to-equity ratio of 0.41.

Definitive Healthcare (NASDAQ:DH) last announced its quarterly earnings results on Thursday, November 6th. The company reported $0.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.01. Definitive Healthcare had a positive return on equity of 3.30% and a negative net margin of 77.88%.The business had revenue of $60.05 million for the quarter, compared to the consensus estimate of $59.51 million. Definitive Healthcare has set its FY 2025 guidance at 0.230-0.240 EPS and its Q4 2025 guidance at 0.050-0.060 EPS. Analysts anticipate that Definitive Healthcare will post 0.16 earnings per share for the current year.

Hedge Funds Weigh In On Definitive Healthcare

Several institutional investors have recently modified their holdings of DH. SG Americas Securities LLC acquired a new stake in shares of Definitive Healthcare in the 4th quarter worth about $46,000. Cambria Investment Management L.P. acquired a new stake in shares of Definitive Healthcare in the third quarter valued at approximately $145,000. Ariadne Wealth Management LP bought a new stake in shares of Definitive Healthcare during the third quarter valued at approximately $54,000. PharVision Advisers LLC acquired a new position in shares of Definitive Healthcare during the third quarter worth approximately $120,000. Finally, Prelude Capital Management LLC bought a new position in Definitive Healthcare in the 3rd quarter worth approximately $64,000. Institutional investors own 98.67% of the company’s stock.

About Definitive Healthcare

Definitive Healthcare (NASDAQ:DH) is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.

The company’s flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.